FDA cleared the investigational new drug application for ZW191, a novel folate receptor-α targeted topoisomerase I inhibitor antibody-drug conjugate sponsored by Zymeworks.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
